कृपया अन्य खोज का प्रयास करें
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Olivier Litzka | 55 | 2022 | Independent Director |
Srinivas Akkaraju | 56 | 2021 | Independent Director |
James Matthew Luther | - | - | Member of Clinical Advisory Board |
Glenn P. Sblendorio | 68 | 2023 | Independent Director |
Alexander G. Asam | 58 | 2021 | Independent Director |
Matthew R. Weir | - | - | Member of Clinical Advisory Board |
Joseph Loscalzo | 73 | - | Member of Clinical Advisory Board |
Derek Paul DiRocco | 43 | 2022 | Independent Director |
Daphne Karydas | 51 | 2023 | Independent Director |
Jon Congleton | 61 | 2020 | CEO & Director |
Brian Taylor Slingsby | 47 | 2019 | Founder & Executive Chairman |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है